A phase 2, multicenter, randomized, double-blinded, and placebo-controlled study of the antiviral activity, safety and pharmacokinetics of VCH-759 in subjects with chronic hepatitis C-infection.

Trial Profile

A phase 2, multicenter, randomized, double-blinded, and placebo-controlled study of the antiviral activity, safety and pharmacokinetics of VCH-759 in subjects with chronic hepatitis C-infection.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2009

At a glance

  • Drugs Hepatitis C virus NS 5 protein inhibitors; VCH 759
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2009 Company (Vertex Pharmaceuticals) added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Results published in the Journal of Hepatology.
    • 25 Jul 2007 Status change from recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top